vs
Apellis Pharmaceuticals, Inc.（APLS）与UL Solutions Inc.（ULS）财务数据对比。点击上方公司名可切换其他公司
UL Solutions Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$340.0M vs $199.9M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -12.4%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -31.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
UL是总部位于美国伊利诺伊州诺斯布鲁克的全球私营安全领域企业，旗下设有三大机构：UL研究院、UL标准与倡议部门以及UL Solutions，为全球各行业客户提供标准制定、检测认证、风险管控等专业安全服务，保障产品与运营的合规性与安全性，助力企业可持续发展。
APLS vs ULS — 直观对比
营收规模更大
ULS
是对方的1.7倍
$199.9M
营收增速更快
APLS
高出6.4%
-12.4%
两年增速更快
APLS
近两年复合增速
-31.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $340.0M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 24.4% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -12.4% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSULS
| Q1 26 | — | $340.0M | ||
| Q4 25 | $199.9M | $789.0M | ||
| Q3 25 | $458.6M | $783.0M | ||
| Q2 25 | $178.5M | $776.0M | ||
| Q1 25 | $166.8M | $705.0M | ||
| Q4 24 | $212.5M | $739.0M | ||
| Q3 24 | $196.8M | $731.0M | ||
| Q2 24 | $199.7M | $730.0M |
净利润APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | $67.0M | ||
| Q3 25 | $215.7M | $100.0M | ||
| Q2 25 | $-42.2M | $91.0M | ||
| Q1 25 | $-92.2M | $67.0M | ||
| Q4 24 | $-36.4M | $81.0M | ||
| Q3 24 | $-57.4M | $88.0M | ||
| Q2 24 | $-37.7M | $101.0M |
毛利率APLSULS
| Q1 26 | — | — | ||
| Q4 25 | — | 49.7% | ||
| Q3 25 | — | 50.3% | ||
| Q2 25 | — | 49.4% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 47.4% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 50.1% |
营业利润率APLSULS
| Q1 26 | — | 24.4% | ||
| Q4 25 | -25.6% | 15.0% | ||
| Q3 25 | 48.7% | 19.9% | ||
| Q2 25 | -18.6% | 17.9% | ||
| Q1 25 | -50.0% | 15.5% | ||
| Q4 24 | -12.3% | 15.6% | ||
| Q3 24 | -24.0% | 17.8% | ||
| Q2 24 | -14.7% | 17.3% |
净利率APLSULS
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | 8.5% | ||
| Q3 25 | 47.0% | 12.8% | ||
| Q2 25 | -23.6% | 11.7% | ||
| Q1 25 | -55.3% | 9.5% | ||
| Q4 24 | -17.1% | 11.0% | ||
| Q3 24 | -29.2% | 12.0% | ||
| Q2 24 | -18.9% | 13.8% |
每股收益（稀释后）APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $0.33 | ||
| Q3 25 | $1.67 | $0.49 | ||
| Q2 25 | $-0.33 | $0.45 | ||
| Q1 25 | $-0.74 | $0.33 | ||
| Q4 24 | $-0.30 | $0.40 | ||
| Q3 24 | $-0.46 | $0.44 | ||
| Q2 24 | $-0.30 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $295.0M | ||
| Q3 25 | $479.2M | $255.0M | ||
| Q2 25 | $370.0M | $272.0M | ||
| Q1 25 | $358.4M | $267.0M | ||
| Q4 24 | $411.3M | $298.0M | ||
| Q3 24 | $396.9M | $327.0M | ||
| Q2 24 | $360.1M | $295.0M |
总债务APLSULS
| Q1 26 | — | — | ||
| Q4 25 | — | $491.0M | ||
| Q3 25 | — | $544.0M | ||
| Q2 25 | — | $608.0M | ||
| Q1 25 | — | $653.0M | ||
| Q4 24 | — | $742.0M | ||
| Q3 24 | — | $797.0M | ||
| Q2 24 | — | $810.0M |
股东权益APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $1.3B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $970.0M | ||
| Q4 24 | $228.5M | $904.0M | ||
| Q3 24 | $237.1M | $872.0M | ||
| Q2 24 | $264.3M | $769.0M |
总资产APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $2.9B | ||
| Q3 25 | $1.1B | $2.9B | ||
| Q2 25 | $821.4M | $2.9B | ||
| Q1 25 | $807.3M | $2.9B | ||
| Q4 24 | $885.1M | $2.8B | ||
| Q3 24 | $901.9M | $2.9B | ||
| Q2 24 | $904.5M | $2.7B |
负债/权益比APLSULS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 1.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $144.0M | ||
| Q3 25 | $108.5M | $155.0M | ||
| Q2 25 | $4.4M | $147.0M | ||
| Q1 25 | $-53.4M | $154.0M | ||
| Q4 24 | $19.4M | $130.0M | ||
| Q3 24 | $34.1M | $150.0M | ||
| Q2 24 | $-8.3M | $103.0M |
自由现金流APLSULS
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $86.0M | ||
| Q3 25 | $108.3M | $109.0M | ||
| Q2 25 | $4.4M | $105.0M | ||
| Q1 25 | $-53.4M | $103.0M | ||
| Q4 24 | $19.3M | $72.0M | ||
| Q3 24 | — | $84.0M | ||
| Q2 24 | $-8.4M | $47.0M |
自由现金流率APLSULS
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 10.9% | ||
| Q3 25 | 23.6% | 13.9% | ||
| Q2 25 | 2.5% | 13.5% | ||
| Q1 25 | -32.0% | 14.6% | ||
| Q4 24 | 9.1% | 9.7% | ||
| Q3 24 | — | 11.5% | ||
| Q2 24 | -4.2% | 6.4% |
资本支出强度APLSULS
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 7.4% | ||
| Q3 25 | 0.0% | 5.9% | ||
| Q2 25 | 0.0% | 5.4% | ||
| Q1 25 | 0.0% | 7.2% | ||
| Q4 24 | 0.0% | 7.8% | ||
| Q3 24 | 0.0% | 9.0% | ||
| Q2 24 | 0.0% | 7.7% |
现金转化率APLSULS
| Q1 26 | — | — | ||
| Q4 25 | — | 2.15× | ||
| Q3 25 | 0.50× | 1.55× | ||
| Q2 25 | — | 1.62× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 1.60× | ||
| Q3 24 | — | 1.70× | ||
| Q2 24 | — | 1.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ULS
暂无分部数据
